Drug Discovery@nature.com 22 November 2013

Advertisement This Is Your Brain on Drugs Highly pure, human iPSC-derived iCell® Neurons for biologically relevant & reproducible results Amenable to electrophysiology, neurite outgrowth, toxicity & drug screening assays Published validation in peer-reviewed journals Easy-to-use kits TABLE OF CONTENTS 22 November 2013 News Analysis Research Highlights Research & Reviews Careers Advertisement   Reichert Life Sciences Surface Plasmon Resonance (SPR) Systems - Drug discovery instruments for real-time, label-free results Reichert SPR systems generate precise kinetics (on/off rates), affinity and thermodynamics data for lead optimization. The ultra-sensitive systems are flexible and affordable. Read citations of Reichert systems in peer-reviewed abstracts.   ReichertSPR.com Nature Reviews Drug Discovery is on Twitter Advertisement Nature Immunology  FOCUS ON TISSUE-RESIDENT LEUKOCYTES Tissue-resident immune cells communicate with resident stromal cells to patrol and monitor against infection and tissue damage. Nature Immunology presents five specially commissioned Reviews that discuss interactions and functions of tissue-resident leukocytes within nonlymphoid tissues during healthy steady state, upon infection and within tumor environments.    News Top Cancer immunotherapy advances spawn calls for new endpoints doi:10.1038/nm1113-1357 Mixed responses to certain cancer immunotherapies - with progression in some lesions and regression in others – have led to the call for additional ‘immune-related’ responses to be incorporated into surrogate endpoints for cancer immunotherapy trials. Full Text Small nanobody drugs win big backing from pharma doi:10.1038/nm1113-1355 The flurry of deals that Ablynx has inked with various pharma companies suggests that nanobodies from camelids are now proving their clinical worth. Full Text Monoclonal T-cell receptor drugs pique pharma's interest doi:10.1038/nbt1113-950b The ability of Immunocore’s fusion proteins to co-opt T-cells into attacking intracellular targets that are inaccessible to monoclonal antibodies has attracted GSK and Genentech to enter into partnerships with the biotech company. Full Text Anti-infective monoclonals step in where antimicrobials fail doi:10.1038/nbt1113-952b Anti-infective mAbs are poised for resurgence owing to their specificity of action, safety and the lack of resistance or cross-resistance with other antimicrobials. Full Text Analysis Top Trends with benefits doi:10.1038/scibx.2013.1245 The FDA set up its adverse event database to capture the side effects of marketed drugs, but US researchers have now exploited the resource to extract new information - beneficial combinations that reduce a drug’s risk of toxicity. The synergies could provide new targets to help guide drug discovery. Full Text Advances in prostate cancer treatment doi:10.1038/nrd4068 This article examines current and upcoming treatment modalities and provides a market outlook for prostate cancer. Full Text Research Highlights Top Anticancer drugs: IDH2 drives cancer in vivo doi:10.1038/nrd4160 Two recent studies show that mutations in the metabolic gene isocitrate dehydrogenase 2 (IDH2) can drive the development of leukaemia and sarcoma in vivo. Full Text Neurodegenerative disorders: A PIR-fect storm doi:10.1038/nrd4159 This study shows that ‘immune receptors’ may have a role in Alzheimer’s disease and points to leukocyte immunoglobulin-like receptor B2 (LILRB2) as a potential therapeutic target for this disorder. Full Text Lysosomal storage diseases: Thioesterase mimetic reduces toxicity doi:10.1038/nrd4156 This study reports a small hydroxylamine derivative that delayed neurological deterioration and extended lifespan in a mouse model of infantile neuronal ceroid lipofuscinosis (INCL) - a neurodegenerative lysosomal storage disease. Full Text Research & Reviews Top Metabolic targets for cancer therapy doi:10.1038/nrd4145 Here, the authors discuss the intimate relationship between metabolism and malignancy, focusing on therapeutic strategies and emerging agents targeting the metabolic rearrangements of cancer cells. Full Text Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain doi:10.1038/nrd3893 Glycine transporters are important regulators of the level of glycine, which can act as both an inhibitory neurotransmitter and a modulator of neuronal excitation. Here, the authors discuss the potential of glycine transporters as novel therapeutic targets for schizophrenia, alcohol dependence and pain. Full Text Immunological functions of the neuropilins and plexins as receptors for semaphorins doi:10.1038/nri3545 Semaphorins and their primary receptors, the neuropilins and plexins, participate in a wide range of innate and adaptive immune responses, which has implications for immune disorders such as multiple sclerosis, rheumatoid arthritis and allergy. Full Text Microbiota-mediated colonization resistance against intestinal pathogens doi:10.1038/nri3535 Colonization resistance - protection from exogenous pathogens by commensal bacteria - can be mediated by direct antagonism and by indirect effects on the host immune response. This Review outlines our current knowledge of immune-mediated colonization resistance against clinically relevant, antibiotic-resistant intestinal pathogens and how insights into commensal bacterial species and their mechanisms might be therapeutically used to restore resistance. Full Text Drug Discovery JOBS of the week Post-Doctoral Grant in Molecular Modeling and Drug Design University of Evora Postdoctoral Researcher in Biomaterials and Drug Delivery Vanderbilt University, Department of Chemical and Biomolecular Engineering Chemistry Faculty Position, Drug Discovery Department, Moffitt Cancer Center Moffitt Cancer Center Postdoctoral fellow in human liver tissue engineering for drug and toxicology studies. Duke University Biomedical Engineering Department More Science jobs from Drug Discovery EVENT The Biology of Aging: Novel Drug Targets for Neurodegenerative Disease 09.05.14 New York, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.